學習經歷
2012-2016 河北科技大學，學士
2016-2022 華東理工大學，博士
工作經歷
2022-2023 石藥集團☀️，高級研究員
2023-至今 EON体育4登录，副教授
教學工作
本科生課程⚪️🌟：
專業核心課《藥物化學》💅、《製藥過程安全與環保》、《藥物代謝動力學》🧔🏿♂️、《藥物毒理學》
研究生課程：
《生物安全》
主要研究方向及領域
1.基於虛擬篩選以及基於結構的藥物研究。
2.抗腫瘤藥物的設計🏌🏻💇、合成與生物活性評價👨🏽🌾。
3.抗病毒藥物的設計、合成及抗病毒活性的研究。
主持課題項目
1.河北省省屬高校基本科研業務費研究項目，抗流感病毒小分子藥物的合成和活性測試研究，2023-2025，KY2023041，主持📒👷。
2.EON体育4引進人才科研專項，廣譜抗病毒小分子抑製劑的設計、合成及活性測試研究，2023-2027，YJ2023014🧑🏻🎨，主持👸。
3.河北省科技特派員，2023🎮。
代表性學術成果
研究論文（*通訊作者）🍷💆🏽♀️：
1.Dou Dou; Yanyan Diao; Wenjie Sha; Rongrong Su; Linjiang Tong; Wenjie Li; Limin Leng; Lijuan Xie; Zhixiao Yu; Haoming Song; Zihao Shen; Lili Zhu; Zhenjiang Zhao; Hua Xie; Zhuo Chen; Honglin Li; Yufang Xu ; Discovery of pteridine-7(8H)-one derivatives as potent and selective inhibitors of Bruton’s tyrosine kinase (BTK), Journal of Medicinal Chemistry, 2022, 65: 2694. (一區Top)
2.Dou Dou; Jie Wang; Yunjin Qiao; Gulinuer Wumaier; Wenjie Sha; Wenjie Li; Wenyi Mei; Tingyuan Yang; Chen Zhang; Huan He; Caolin Wang; Linna Chu; Baihui Sun; Rongrong Su; Xiangyu Ma; Mengdie Gong; Lijuan Xie; Wenzhe Jiang; Yanyan Diao; Lili Zhu; Zhenjiang Zhao; Zhuo Chen; Yufang Xu; Shengqing Li; Honglin Li ; Discovery and optimization of 4-anilinoquinazoline derivatives spanning ATP binding site and allosteric site as effective EGFR-C797S inhibitors, European Journal of Medicinal Chemistry, 2022, 244: 114856 . (一區Top)
3.Dou Dou; Xingsen Zhang; Jie Wang; Gulinuer Wumaier; Yunjin Qiao; Lijuan Xie; Wenzhe Jiang; Wenjie Sha; Wenjie Li;Wenyi Mei; Chen Zhang; Huan He; Caolin Wang; Lingkang Wu; Yanyan Diao; Lili Zhu; Zhenjiang Zhao; Zhuo Chen; Yufang Xu; Shengqing Li; Honglin Li; Design, synthesis, and biological evaluation of diphenyl ether substituted quinazolin-4-amine derivatives as potent EGFRL858R/T790M/C797S inhibitors. European Journal of Medicinal Chemistry, 2024, 279:116858. (一區Top)
4.Dou Dou; Wenjie Sha; Yanyan Diao; Rongrong Su; Yunjin Qiao; Zhixiao Yu; Zhenjiang Zhao; Honglin Li; Zhuo Chen; Yufang Xu; Discovery of pyrido[3,4-b]indol-1-one derivatives as novel non-covalent Bruton’s tyrosine kinase (BTK) inhibitors, Bioorganic Chemistry, 2022, 119: 105541. (一區Top)
5.Mengzhen Lai; Peiran Song; Dou Dou; Yanyan Diao; Linjiang Tong; Tao Zhang; Hua Xie; Honglin Li; Jian Ding; Discovery and biological evaluation of N-(3-(7-((2-methoxy-4-(4 methylpiperazin-1-yl)phenyl)amino)-4-methyl-2-oxo-2H-pyrimido[4,5-d][1,3]oxazin-1(4H) yl)phenyl)acrylamide as potent Bruton’s tyrosine kinase inhibitors, Acta Pharmacologica Sinica, 2020, 41: 415. (共同一作，一區Top)
6.Ruiying Liang; Dou Dou; Chunying Wang; Shanshan Huo; Yang Wu; Juan Wang; Zhengsen Yu; Shuomin Zhang; Jingjing Xu; Yue Liu; Peng Liu; Shibo Jiang; Fei Yu; ADS-J21 is a novel HIV-1 entry inhibitor targeting gp41.Current Research in Microbial Sciences, 2024, 7: 100260. (共同一作)
7.Chao Wang; Huan Wang; Xinling Wang; Lujia Sun; Qian Wang; Qing Li; Ruiying Liang; Dou Dou; Fei Yu; Lu Lu; Shibo Jiang ; Multitargeted drug design strategy for discovery of short- peptide-based HIV-1 entry inhibitors with high potency, European Journal of Medicinal Chemistry, 2023, 252: 115294. (一區Top)
8.Yanbai Li; Zhe Yin; Juan Wang; Yujuan Xu; Shanshan Huo; Yang Wu; Dou Dou; Qingan Han; Shibo Jiang; Feng Li; Peng Liu; Fei Yu, Surveillance of avian influenza viruses in Hebei Province of China from 2021 to 2023: Identification of a novel reassortant H3N3. J Infect. 2024, 89(4):106240.
發明專利🪅🚍：
1.李洪林; 徐玉芳; 趙振江; 蘇榮榮; 刁妍妍; 豆豆; 作為BTK抑製劑的喹喔啉酮類衍生物及其應用, 2021-05-20, 中國, CN202110554269.4.
2.李洪林; 趙振江; 徐玉芳; 陳卓; 朱麗麗; 豆豆; 李文傑; 喬運錦; 王潔; 喹啉及喹唑啉類化合物作為第四代EGFR抑製劑及其應用, 2021-05-26, 中國, CN202110580354.8.
3.李洪林; 趙振江; 陳卓; 徐玉芳; 刁妍妍; 豆豆; 沙文婕; 李文傑; 作為BTK抑製劑的7(8H)-喋啶酮衍生物及其應用, 2021-12-21, 中國, CN202111573921.3.
